Stocktoria
Aptevo Therapeutics Inc. APVO
Aptevo Therapeutics Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M | $4.3M | $32.4M | $23.1M | $14.7M | $10.0M |
| R&D expense | $14.5M | $14.4M | $17.1M | $17.9M | $19.0M | $17.9M | $24.8M | $35.4M | $29.0M | $29.1M |
| SG&A expense | — | — | — | — | — | — | $25.3M | $28.1M | $34.6M | $36.2M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M | -$27.5M | -$41.0M | -$51.7M | -$53.9M | -$138.8M |
| Income tax | $0 | — | — | — | — | — | — | — | -$23.3M | -$19.7M |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M | -$17.8M | -$40.4M | -$53.7M | $7.0M | -$112.4M |
| EPS (diluted) | $-87.27 | $-31460.23 | $-2316.83 | $1.57 | $-6.07 | — | — | — | — | — |
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M | -$29.3M | -$42.4M | -$51.4M | -$41.6M | -$36.9M |
| Free cash flow | — | — | — | -$21.1M | -$22.4M | -$29.4M | -$42.5M | -$52.4M | -$43.0M | -$39.4M |
| Cash & equivalents | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M | $40.0M | $12.4M | $30.6M | $7.1M | $9.7M |
| Inventory | — | — | — | — | — | — | $6.1M | $1.8M | $1.0M | $461,000 |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M | $53.5M | $53.4M | $67.5M | $117.0M | $91.9M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M | $37.0M | $41.6M | $37.1M | $35.0M | $41.3M |
| Shareholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M | $16.6M | $11.8M | $30.4M | $82.0M | $50.6M |
Growth · year-over-year · Revenue CAGR -17.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | -74.7% | +185.3% | -86.7% | +40.6% | +57.4% | +46.8% | -70.3% |
| Net income growth | — | — | -316.9% | — | — | — | — | -870.0% | — | — |
| EPS growth | — | — | -147668.8% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.